Paying up for reduced risk is often worth it when investing in biotech stocks. Even with two drugs on the market, Alnylam is still some distance from being profitable; those pipeline drug candidates …
More Second RNAi Drug Approved: Biotech Investors Should Pay Attention to This New Drug Class Videos